Placebo matching and without active substance clinical trials

A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period

This study is testing a new medicine called Bepranemab for people with early Alzheimer's disease. Researchers want to see if it's safe and helps with memory and thinking, compared to a dummy drug. It's a key step in understanding if this treatment could work.